Cargando…

PB2039: CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROM-BOCYTHEMIA，PREFIBROTIC PRIMARY MYELOFIBROSIS, AND OVERT FIBROTIC PRIMARY MYELOFIBROSIS: A CHINESE RETROSPECTIVE STUDY

Detalles Bibliográficos
Autores principales:	Huang, J., Zhang, L., Ye, X.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Publication Only
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9429196/ http://dx.doi.org/10.1097/01.HS9.0000850988.97140.88

Ejemplares similares

PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY
por: Kaynak, Emine, et al.
Publicado: (2023)

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis
por: Coltro, Giacomo, et al.
Publicado: (2022)

Survival expectation after thrombosis and overt-myelofibrosis in essential thrombocythemia and prefibrotic myelofibrosis: a multistate model approach
por: Carobbio, Alessandra, et al.
Publicado: (2023)

PB2211: DIFFERENCES IN POST-POLYCYTHEMIA VERA AND POST–ESSENTIAL THROMBOCYTHEMIA MYELOFIBROSIS VS PRIMARY MYELOFIBROSIS IN FIBROTIC STAGE: A RETROSPECTIVE, REAL-WORLD STUDY CONDUCTED IN CHINA
por: Wang, Shengjie, et al.
Publicado: (2023)

Evidence that Prefibrotic Myelofibrosis Is Aligned along a Clinical and Biological Continuum Featuring Primary Myelofibrosis
por: Barosi, Giovanni, et al.
Publicado: (2012)

Mutational spectrum and prognosis in Chinese patients with prefibrotic primary myelofibrosis
por: Cheng, Chi‐Keung, et al.
Publicado: (2021)

Prefibrotic myelofibrosis: treatment algorithm 2018
por: Finazzi, Guido, et al.
Publicado: (2018)

Thrombosis in essential thrombocytemia and early/prefibrotic primary myelofibrosis: the role of the WHO histological diagnosis
por: Rupoli, Serena, et al.
Publicado: (2015)

Easily Applicable Predictive Score for Differential Diagnosis of Prefibrotic Primary Myelofibrosis from Essential Thrombocythemia
por: Lekovic, Danijela, et al.
Publicado: (2023)

PB2230: THE ORIGIN IN PRIMARY AND SECONDARY MYELOFIBROSIS: IS THE KEY THE PROGENITOR OR THE MOLECULAR SIGNATURE?
por: Cuadrado, Isabel Montero
Publicado: (2023)

PB2173: THE EFFECT OF RUXOLITINIB THERAPY ON HEMOSTATIC PARAMETERS IN PATIENTS WITH PRIMARY MYELOFIBROSIS
por: Korsakova, Natalia, et al.
Publicado: (2023)

Validation of the IPSET score for thrombosis in patients with prefibrotic myelofibrosis
por: Guglielmelli, Paola, et al.
Publicado: (2020)

Coexistence of Plasma Cell Dyscrasia with Prefibrotic Stage of Primary Myelofibrosis: A Case Report
por: Tsirakis, George, et al.
Publicado: (2011)

PB2206: PROGRESSION FACTORS OF MYELOFIBROSIS BASED ON CLINICAL FEATURES AND NEXT-GENERATION SEQUENCING LANDSCAPE OF ESSENTIAL THROMBOCYTHEMIA: A CHINES TWO-CENTER RETROSPECTIVE STUDY
por: Xiang, Danhong, et al.
Publicado: (2023)

PB2055: A RARE CASE OF HIGH-RISK HEREDITARY THROMBOPHILIA COMBINED WITH PRIMARY MYELOFIBROSIS
por: Khoduleva, S., et al.
Publicado: (2022)

PB2166: PRIMARY MYELOFIBROSIS: SERUM LACTATE DEHYDROGENASE AS A PREDICTOR OF EARLY LEUKEMIC PROGRESSION
por: Moura, Pedro, et al.
Publicado: (2023)

Immune Complex Associated Glomerulonephritis in a Patient with Prefibrotic Primary Myelofibrosis: A Case Report
por: Atlani, Mahendra, et al.
Publicado: (2021)

PB2052: CLINICOPATHOLOGIC VARIABLES AFFECTING DISEASE OUTCOME IN PRIMARY MYELOFIBROSIS. A SINGLE CENTER EXPERIENCE.
por: Elkourashy, S., et al.
Publicado: (2022)

PB2051: PRIMARY MYELOFIBROSIS IN YOUNG PATIENTS ≤50 YEARS: CLINICOPATHOLOGICAL CHARACTERISTICS, GENETIC LANDSCAPE AND DISEASE OUTCOME. A SINGLE CENTER EXPERIENCE
por: Elkourashy, S., et al.
Publicado: (2022)

A multistate model of survival prediction and event monitoring in prefibrotic myelofibrosis
por: Carobbio, Alessandra, et al.
Publicado: (2020)

PB2196: CLINICAL IMPACT OF NUTRITIONAL STATUS AND NUTRITIONAL MONITORING IN PRIMARY MYELOFIBROSIS PATIENTS: PRELIMINARY RESULTS OF NUTRIMY STUDY
por: Malchiodi, Margherita, et al.
Publicado: (2023)

Clinical course and outcome of essential thrombocythemia and prefibrotic myelofibrosis according to the revised WHO 2016 diagnostic criteria
por: Rumi, Elisa, et al.
Publicado: (2017)

A 7-Gene Signature Depicts the Biochemical Profile of Early Prefibrotic Myelofibrosis
por: Skov, Vibe, et al.
Publicado: (2016)

Coexistence of Prefibrotic Myelofibrosis with Monoclonal Gammopathy of Undetermined Significance: A Case Report
por: Ismail, Omar M., et al.
Publicado: (2021)

PB2231: AN OVERLOOKED MIMIC? AUTOIMMUNE MYELOFIBROSIS - A SCOPING REVIEW OF THE LITERATURE
por: Riazat-Kesh, Yosef Joseph Rene Amel, et al.
Publicado: (2023)

PB2251: SOMETIMES IT’S ZEBRAS: SUCCESSFUL TREATMENT OF ERYTHROPOIETIC PROTOPORPHYRIA POST PRIMARY MYELOFIBROSIS WITH GIVOSIRAN - A CASE REPORT
por: Catana, Alina, et al.
Publicado: (2023)

A study of (18)F-FLT positron emission tomography/computed tomography imaging in cases of prefibrotic/early primary myelofibrosis and essential thrombocythemia
por: Yassin, Mohamed A., et al.
Publicado: (2020)

PB2056: MYELOFIBROSIS IN PATIENTS OLDER THAN 70 YEARS: IS TREATMENT WITH RUXOLITINIB WORTH IT?
por: Montero, M. I.
Publicado: (2022)

PB2048: EFFICACY AND SAFETY OF RUXOLITINIB IN PATIENTS WITH MYELOFIBROSIS: A RETROSPECTIVE MULTICENTER STUDY
por: Chen, C., et al.
Publicado: (2022)

PB2203: INCIDENCE AND PREVALENCE OF MYELOFIBROSIS IN GERMANY: A RETROSPECTIVE CLAIMS DATA ANALYSIS
por: Junker, Sophia, et al.
Publicado: (2023)

PB2220: ATRIAL FIBRILLATION IS FREQUENT IN PATIENTS WITH MYELOFIBROSIS AND MIGHT BE SUB-OPTIMALLY TREATED
por: Lucijanic, Marko, et al.
Publicado: (2023)

P1043: OUTCOME OF PATIENTS WITH PREFIBROTIC MYELOFIBROSIS FROM A LARGE ACADEMIC CENTER
por: Masarova, L., et al.
Publicado: (2022)

PB2060: THE MDS-SPECIFIC COMORBIDITY INDEX (MDS-CI) PREDICTS SURVIVAL INDEPENDENTLY FROM DIPSS AND MIPSS70 IN PATIENTS WITH OVERT MYELOFIBROSIS NOT ELIGIBLE FOR ALLOGENEIC STEM CELL TRANSPLANTATION.
por: Koster, K.-L., et al.
Publicado: (2022)

PB2039: INFLAMMATORY MARKERS IN HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS - A SINGLE CENTRE STUDY
por: Goubran, Mariam, et al.
Publicado: (2023)

Essential thrombocythemia vs. pre-fibrotic/early primary myelofibrosis: discrimination by laboratory and clinical data
por: Schalling, Martin, et al.
Publicado: (2017)

Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary Myelofibrosis
por: Cattaneo, Daniele, et al.
Publicado: (2022)

Prefibrotic Myelofibrosis Presenting with Multiple Cerebral Embolic Infarcts and the Rare MPL W515S Mutation
por: Langabeer, Stephen E., et al.
Publicado: (2020)

Fibrocytes in primary myelofibrosis
por: Shimoda, Kazuya, et al.
Publicado: (2021)

Assessing Bone Marrow Activity with [18F]FLT PET in Patients with Essential Thrombocythemia and Prefibrotic Myelofibrosis: A Proof of Concept
por: Yassin, Mohamed A., et al.
Publicado: (2022)

PB2177: MULTICENTRE RETROSPECTIVE OBSERVATIONAL STUDY ON PATIENTS WITH MYELOFIBROSIS IN PIEDMONT. ROLE OF INFLAMMATION AND DYSIMMUNITY. MFACTORS STUDY.
por: Bonuomo, Valentina, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_an8v7ejogrtec15ojqnoq30j47